Vector Science & Therapeutics Corp. Welcomes Russell Starr as New President to Drive Future Growth

The New Leadership Era at Vector Science & Therapeutics Corp.

In a significant move towards future growth, Vector Science & Therapeutics Corp. (TSXV: PAIN) has officially appointed Russell Starr as the new President of the Company, effective October 5, 2026. This development comes as the Company continues to solidify its position within the medical technology landscape, known for its cutting-edge work in drug delivery technology and the manufacturing of pharma-grade peptides.

Russell Starr is not a stranger to the world of capital markets. As a veteran entrepreneur and financier, Starr has played a pivotal role in the advancement of numerous public companies. His extensive experience in navigating complex financing solutions and executing strategic transactions positions him perfectly to lead Vector into its next growth phase. Having assisted in raising over $2 billion for public equities, his expertise is expected to bring substantial value as Vector continues to grow its operations and expand its market presence.

As part of his onboarding, Starr is set to receive a compensation package that includes a full salary in common shares, reflecting his faith in the Company’s potential. Additionally, he has been allocated 1,500,000 options that are linked to specific performance targets, reinforcing the commitment to drive Vector’s stock prices upwards as the company continues its mission.

Vision for the Company

Tommy Thompson, Chairman of Vector Science & Therapeutics, expressed confidence in Starr's leadership, stating, "Russell's judgment and experience building public companies make him exactly the right partner as we enter this next phase." This sentiment is echoed by Bill Jackson, the current Chief Executive Officer, who highlighted Starr's influence in the Company’s journey thus far, emphasizing that together they plan to scale their operations effectively.

From the beginning of his involvement with Vector, Starr has been an advocate for the Company’s mission to innovate in the area of pharma-grade peptides and non-opioid solutions targeted at enhancing longevity and overall well-being. His formal appointment aims to unify the leadership team and ensure a synergistic approach as they advance their pioneering products to market.

What Lies Ahead for Vector

Vector Science & Therapeutics Corp. specializes in delivering advanced drug delivery technologies and pharma-grade peptide manufacturing for applications in the sports medicine, regenerative medicine, and pain management sectors. Unlike many competitors, Vector’s peptides are produced under stringent cGMP, FDA, and ISO-compliant conditions, designed for direct physician use rather than being funneled through research-only channels. Such high standards in manufacturing place Vector at the forefront of medical technology, ensuring that they are not just participants but are leaders in the industry.

With its headquarters in Mequon, Wisconsin, the Company is charting an ambitious course to impact how pharmaceutical-grade peptides are utilized across various medical fields. As Starr steps into his role as President, stakeholders can look forward to a strategic vision that promises not just product development but potentially new healthcare solutions that could redefine patient care.

Under Starr’s leadership, Vector appears poised to explore new heights, focusing on the development of novel delivery systems for their products while amplifying their commitment to innovation. The Company is expected to enhance its market strategy, which may include new partnerships and collaborations designed to bolster its industry position and expand its offerings.

Conclusion

Russell Starr's appointment as President marks a new chapter for Vector Science & Therapeutics Corp. His proven track record in capital markets, combined with his long-standing commitment to the Company's mission, sets a positive stage for the future. As they transition through this pivotal moment, all eyes will be on how Vector harnesses Starr’s leadership to accelerate their growth and solidify their reputation as a leader in the medical technology space.